Moreover, we observed that lower SSTR1 and SSTR2, but not CORT, expression levels were also displayed in tumours harbouring EGFR amplification, another aggressive sign in GBM [43, 44], in the Gravendeel-cohort (Fig. 3F). This evidence concerns the gene SSTR2 and neoplasm.